Rhizome AI

The pharmaceutical industry, representing an $8 trillion market capitalization, requires comprehensive understanding of the Food and Drug Administration's (FDA) perspectives. Rhizome AI addresses this critical need by providing a platform that enables users to obtain answers to their questions, supported by citations from up to 1,000 relevant documents. This information is extracted from terabytes of authoritative regulatory and clinical databases, ensuring accuracy and reliability.

Chetan, the founder, transitioned from a research engineering background to focus on product development. His experience includes being the founding product engineer at EvolutionaryScale, where he launched their developer-scientist platform and scaled it to serve tens of thousands of users and billions of API calls. He also held a key role at Instabase, assisting banks with document and imaging processing, and securing $7 million in deals as the technical lead.

Recognizing a gap in the AI landscape, Chetan observed numerous AI-driven drug discovery companies but a scarcity of AI solutions focused on navigating the complexities of bringing drugs to market. Through conversations with industry professionals, he identified the significant challenge and expense associated with understanding FDA regulations and guidelines. Rhizome AI's initial product, Rhizome Ask, achieved six-figure revenue within its first year, demonstrating the value and demand for its services.